Business Wire

CA-ALVEO-TECHNOLOGIES

17.11.2022 15:46:40 CET | Business Wire | Press release

Share
Alveo Technologies Announces New Executive Leadership, Open Platform Strategy

Alveo Technologies, Inc. (Alveo) today announced the appointment of three life sciences industry leaders to its senior executive team to advance the development of its novel molecular sensing and diagnostics technology and lead the company through strategic growth and commercialization of its rapid, multiplexed molecular diagnostic platform, be.well™. The company, seeking to catalyze broader adoption of its highly differentiated platform, is actively seeking collaborators to rapidly expand the menu of assays available within healthcare and beyond.

The innovative be.well™ platform, a prior X-Prize winner, pairs advanced molecular assays with secure, HIPAA- and GDPR-compliant cloud-enabled data analytics for real-time disease, pathogen and contaminant diagnoses, detection, and analysis. Designed to bring molecular sensing and diagnostics closer to the point of need, whether at the point of care, over the counter, at home, or in the field, the rapid, handheld and portable be.well™ platform can be customized to detect a wide range of diseases including COVID-19, Influenza A/B, and RSV, sexually transmitted infections and urinary tract infections as well as applications for veterinary, agricultural, and other industrial markets where low cost, accurate, rapid molecular testing, sampling, or detection capabilities are needed.

New Executive Leadership to Ensure Universal Access to Groundbreaking Technology

Shaun Holt, Chief Executive Officer, and Chairman of the Board of Directors

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

Erik Tyrrell-Knott, Chief Business and Strategy Officer

As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering, and product management efforts, driving the Company’s commercial, partnership, and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Slava Elagin, PhD, MBA, Chief Technology Officer

Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industries. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences, and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.

Proprietary Advanced Molecular Sensing Technology Offers Distinct Advantages

Alveo is leading the transformation of the point-of-need molecular sensing and health tech markets with an “open platform” approach to co-developing rapid molecular testing capabilities with collaborative partners across multiple markets.

“Alveo has spent seven years and more than $70 million dollars developing a bulletproof, mobile “Molecular Lab” that can deliver exquisitely sensitive and specific testing wherever, whenever it is needed: literally in the field for crop testing, on farms for animal testing, and most importantly in labs, pharmacies, and doctors’ offices for various infectious diseases,” says CEO Shaun Holt. “The future of healthcare, and molecular sensors as a whole, lies closer and closer to the patient or point of need, and the multiplexed Alveo platform will deliver insight and guidance with zero compromise.”

The be.well™ platform is the only point-of-care diagnostic platform available today that utilizes Alveo’s proprietary and globally patented method for the direct electrical sensing of nucleic acid amplification. This technology eliminates the need for specialized lighting and expensive optical detectors, while also simplifying certain aspects of primer manufacturing, providing a more robust and reliable diagnostic instrument.

Alveo’s platform can be used with various specimen types, such as nasal, blood, or urine samples, which eliminates the need to modify the platform design for different disease applications. The design architecture -- with a total of 15 components -- is reusable and rechargeable, Bluetooth- and cloud-enabled, with no moving parts or hazardous waste, is environmentally friendly, reduces manufacturing costs and limits supply chain risk. The simplicity of the detection methodology, its lower cost compared to other single-use diagnostic tests, and its wide range of health and disease applications are key advantages driving Alveo’s commercialization partnerships.

“A seminal pillar of Alveo’s growth is to open our platform to companies with expertise, market reach, and customer insights that extend beyond what Alveo can accomplish on our own,” says Erik Tyrrell-Knott. “Collaborating with partners to take molecular testing out of the lab, into new markets, and deliver actionable insights at the point of need is our core focus. The doors are open, and we are ready to co-develop.”

Alveo’s be.well™ COVID-19 Test received CE (Conformité Européene) Mark regulatory approval and the company is initially scaling up production for commercialization in the United Kingdom and European Union. Alveo is also actively pursuing 510(K) clearance from the U.S. Food and Drug Administration.

About Alveo

At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.

To learn more, visit https://alveotechnologies.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005419/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release

Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release

European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res

Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release

Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work

Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release

Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf

New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release

New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye